CYP2C9 genetic variants and losartan oxidation in a Turkish population

Babaoglu, MO; Yasar, ÜMİT; Sandberg, M; Eliasson, E; Dahl, ML; Kayaalp, SO; Bozkurt, ATİLLA

doi:10.1007/s00228-004-0785-5

CYP2C9 genetic variants and losartan oxidation in a Turkish population

Babaoglu M., Yasar U., Sandberg M., Eliasson E., Dahl M., Kayaalp S., ...More

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.5, pp.337-342, 2004 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 60 Issue: 5
Publication Date: 2004
Doi Number: 10.1007/s00228-004-0785-5
Journal Name: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.337-342
Hacettepe University Affiliated: Yes

Abstract

Objective. Cytochrome P-450 2C9 (CYP2C9) is a polymorphic enzyme catalysing the metabolism of several important drugs. Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity. The aim of the study was to determine the activity of CYP2C9, using losartan as a probe drug, in relation to CYP2C9 genotype in healthy Turkish subjects.